Chris Trembath06.15.06
Minneapolis, MN-based Medtronic, Inc., announced European approval and market availabilityof the Concerto/Virtuoso line of implantable devices, which includes the Concerto cardiac resynchronisation therapy-defibrillator (CRT-D) and Virtuoso single- and dual-chamber implantable cardioverter-defibrillators (ICDs). These are Medtronic's first cardiac rhythm disease management devices with wireless telemetry, enabling communication remotely between the implanted device and programmers in a clinician's office, or between the device and a patient home monitor.
With the PatientLook Indicator home monitor, patients can view notifications when their device detects an alert, such asatrial fibrillation, thoracic fluid accumulation, or a device performance issue. If the PatientLook Indicator notes an alert condition, patients are instructed to call their physician. In addition, patients may also manually initiate a self-check to view the status of their condition and get visual notification of their alert status.
The Virtuoso ICDs and Concerto CRT-D can also deliver a shock to terminate a dangerously abnormal heart rhythm. The Concerto CRT-D device also sends tiny electrical impulses to the heart muscle to resynchronisethe contractions of the heart's lower chambers, helping the heart pump blood throughout the body more efficiently. These devices were recently approved by the United States Food and Drug Administration. Other features of the system include: Conexus Wireless Telemetry with SmartRadio Technology; OptiVol Fluid Status Monitoring; Left Ventricular Capture Management; ATP During Charging; and Managed Ventricular Pacing.
"We're raising the level of innovation with the introduction of wireless telemetry, combined with OptiVol Fluid Status Monitoring and the most advanced therapies and diagnostics," said Steve Mahle, president of the Cardiac Rhythm Disease Management business at Medtronic. "The Concerto/Virtuoso line of implantable devices represents the best in cardiac rhythm and disease management."
With the PatientLook Indicator home monitor, patients can view notifications when their device detects an alert, such asatrial fibrillation, thoracic fluid accumulation, or a device performance issue. If the PatientLook Indicator notes an alert condition, patients are instructed to call their physician. In addition, patients may also manually initiate a self-check to view the status of their condition and get visual notification of their alert status.
The Virtuoso ICDs and Concerto CRT-D can also deliver a shock to terminate a dangerously abnormal heart rhythm. The Concerto CRT-D device also sends tiny electrical impulses to the heart muscle to resynchronisethe contractions of the heart's lower chambers, helping the heart pump blood throughout the body more efficiently. These devices were recently approved by the United States Food and Drug Administration. Other features of the system include: Conexus Wireless Telemetry with SmartRadio Technology; OptiVol Fluid Status Monitoring; Left Ventricular Capture Management; ATP During Charging; and Managed Ventricular Pacing.
"We're raising the level of innovation with the introduction of wireless telemetry, combined with OptiVol Fluid Status Monitoring and the most advanced therapies and diagnostics," said Steve Mahle, president of the Cardiac Rhythm Disease Management business at Medtronic. "The Concerto/Virtuoso line of implantable devices represents the best in cardiac rhythm and disease management."